Thermo Fisher Scientific Inc. (NYSE:TMO)‘s stock had its “outperform” rating reissued by equities research analysts at Leerink Swann in a note issued to investors on Sunday. They currently have a $175.00 target price on the stock. Leerink Swann’s target price suggests a potential upside of 20.02% from the company’s current price.

Several other analysts also recently weighed in on TMO. Mizuho set a $175.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Thursday, July 28th. Citigroup Inc. lifted their target price on Thermo Fisher Scientific from $160.00 to $182.00 and gave the company a “buy” rating in a research note on Friday, July 29th. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $178.00 target price on the stock in a research note on Monday, August 1st. Jefferies Group reaffirmed a “hold” rating on shares of Thermo Fisher Scientific in a research note on Thursday, August 4th. Finally, Cleveland Research downgraded Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Friday, September 9th. Two investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $164.37.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Shares of Thermo Fisher Scientific (NYSE:TMO) traded down 2.06% during mid-day trading on Friday, hitting $145.81. The stock had a trading volume of 2,631,666 shares. Thermo Fisher Scientific has a 12-month low of $119.75 and a 12-month high of $160.68. The company has a 50 day moving average price of $152.92 and a 200 day moving average price of $151.85. The firm has a market cap of $57.60 billion, a P/E ratio of 29.14 and a beta of 1.24.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, October 27th. The company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.97 by $0.06. The business had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $4.39 billion. Thermo Fisher Scientific had a return on equity of 14.95% and a net margin of 11.10%. The business’s revenue was up 8.9% on a year-over-year basis. During the same quarter last year, the business posted $1.80 EPS. Equities analysts forecast that Thermo Fisher Scientific will post $8.25 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, January 16th. Stockholders of record on Thursday, December 15th will be given a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $0.60 annualized dividend and a dividend yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 12.00%.

In related news, SVP Daniel P. Shine sold 1,699 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 29th. The stock was sold at an average price of $152.28, for a total transaction of $258,723.72. Following the completion of the sale, the senior vice president now owns 17,437 shares of the company’s stock, valued at $2,655,306.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Thomas W. Loewald sold 913 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 26th. The shares were sold at an average price of $151.92, for a total value of $138,702.96. Following the sale, the insider now directly owns 39,983 shares of the company’s stock, valued at approximately $6,074,217.36. The disclosure for this sale can be found here. 0.52% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. American Research & Management Co. boosted its stake in Thermo Fisher Scientific by 540.0% in the third quarter. American Research & Management Co. now owns 640 shares of the company’s stock worth $102,000 after buying an additional 540 shares during the last quarter. Mycio Wealth Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Mycio Wealth Partners LLC now owns 711 shares of the company’s stock worth $105,000 after buying an additional 11 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Thermo Fisher Scientific by 10.6% in the second quarter. Signaturefd LLC now owns 842 shares of the company’s stock worth $124,000 after buying an additional 81 shares in the last quarter. Penserra Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 100.0% in the third quarter. Penserra Capital Management LLC now owns 864 shares of the company’s stock worth $137,000 after buying an additional 432 shares in the last quarter. Finally, Cable Hill Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 27.1% in the third quarter. Cable Hill Partners LLC now owns 961 shares of the company’s stock worth $152,000 after buying an additional 205 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company is a provider of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

5 Day Chart for NYSE:TMO

Receive News & Stock Ratings for Thermo Fisher Scientific Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc. and related stocks with our FREE daily email newsletter.